We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 23rd Congress of the European Hematology Association in Stockholm. Presentations include; treatment options in resistant CML patients, Does IFN-α improve outcome of CML in the TKI era? and TFR - a new goal for CP-CML patients?

Treatment options in resistant CML patients
Professor Jane Apperley, Imperial College London, UK 

• Patient case history 2013 - 2017
• ELN and NCCN definitions of response and failure
• Outcome of 'real-life' 1st line imatinib by Sokol
• Importance of ACA
• ABL KD mutation sensitivity
• CCyR rates for sequential use of NIL and DAS after IM failure
• 3rd line therapy with Bosutinib
• Relationship of line of therapy to efficacy for PON in 3rd-line vs. 4th line CML
• SCT for CML: the EBMT score